QVance, a Sweden-based specialist in quality analytics for advanced therapies, has entered into an agreement with SKAN to install a pure2 isolator at the company’s Huddinge cleanroom site.
“QVance is proud to be SKAN’s first customer for the pure2 isolator in Sweden,” said Lindsay Davies, CEO of QVance.
SKAN is a Switzerland-based company that provides isolators, cleanroom devices, and decontamination processes, primarily focused on the aseptic production of biopharmaceutical substances.
Benefits of the pure2 system
The pure2 system provides a closed, controlled environment that boosts contamination control, defect risk mitigation and a GMP-compliant environment for handling samples for microbiological testing.
This facility now supports Good Manufacturing Practice (GMP)-compliant sterile handling of test samples, enabling rigorous microbiological analysis critical for product development and release testing across advanced therapy medicinal products (ATMPs).
The demand for localised, high-quality analytical services in the Nordic advanced therapy community has increased.
The increased demand is driven by market growth and the need to overcome development bottlenecks.
As a subsidiary of NextCell Pharma AB, the new collaboration between QVance and SKAN will support the entire lifecycle of cell and gene therapy product development, from early phase analytics to release testing.
